Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514540 · ClinicalTrials.gov registry record · Phase 2
Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT00514540: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00514540 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 121 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00514540, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with anaplastic prostate cancer. Patients who continue to have advanced disease will be switched to etoposide (VePesid) plus cisplatin (Platinol-AQ) to study how effective this second line of chemotherapy is in the treatment of patients iwth anaplastic prostate cancer. The side effects, characteristics of patients who respond, and overall survival will also be studied.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2006-05 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00514540
The ClinicalTrials.gov registry entry for NCT00514540 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00514540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00514540 about?
NCT00514540 is a clinical study titled "Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer". The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with anaplastic prostate cancer. Patients who continue to have advanced disease will be switched to etoposide (VePesid) plus c...
What is the current status of trial NCT00514540?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2006-05. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00514540?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Cisplatin (DRUG), Etoposide (DRUG).
Who is sponsoring clinical trial NCT00514540?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.